AOD-9604 is a topologically intelligent variant of the C-terminal fragment of human growth hormone. Its revolutionary aspect lies in reprogramming the spatiotemporal metabolic logic of white fat cells instead of directly "burning" fat. It precisely activates adipose tissue-specific β3-adrenergic receptors, reconstructing the physiological rhythm of lipolysis pulses, selectively reducing abdominal subcutaneous fat while lowering blood sugar. This is a metabolic "re-education," rather than a violent consumption of energy.
|
Name |
AOD-9604 |
|
Appearance |
White freeze-dried powder |
|
Purity |
99%+ |
|
Minimum order |
10vials/kit |
|
Estate/Nation |
Shenzhen, China |
|
Accepted payment methods |
BTC/USDT/Bank Transfer/Western Union |
|
Transportation time |
Around 10-15days |
Content
AOD9604 is not a crude copy of growth hormone, but rather a precise extraction and modification of its C-terminus (amino acids 176-191). Like a "metabolic task force" dispatched on a single mission, it strips away the anabolic and growth instructions of the parent hormone, retaining only the core code regulating fat metabolism. This task force has a clear objective: to infiltrate adipose tissue and perform the dual tasks of "fat burning" and "preventing fat accumulation," while avoiding triggering systemic endocrine alarms.
Advantages: Precise "metabolic targeting" and excellent safety. Targeting fat metabolism and avoiding endocrine storms: The core advantage of AOD9604 lies in its "functional dissociation" characteristic. It does not bind to the classic growth hormone receptor, nor does it stimulate the secretion of insulin-like growth factor-1 (IGF-1). This means it can mimic the lipolytic effect of growth hormone-stimulating lipolysis and inhibiting lipogenesis-without causing serious side effects associated with systemic growth hormone therapy, such as hyperglycemia, insulin resistance, or acromegaly. It is a precise "metabolic sniper," targeting only fat cells without harming the innocent endocrine system.
In multiple preclinical and early human trials, AOD9604 demonstrated extremely high safety. Neither acute toxicity nor long-term chronic toxicity studies revealed genotoxicity or significant organ toxicity. It showed good tolerability in rat and primate models, with a side effect spectrum indistinguishable from placebo. This "pure" safety record makes it theoretically a highly attractive metabolic regulation tool.
AOD9604 is not a single "fat burner." On one hand, it enhances the lipolytic activity of adipose tissue, accelerating the breakdown of triglycerides into free fatty acids to provide energy for the body; on the other hand, it prevents non-fat substances in the diet from being converted into new body fat. This dual mechanism of "increasing supply and reducing expenditure" gives it a theoretical synergistic advantage in regulating body composition.
"Evidence Gap" in Clinical Efficacy and "Gray Status" in Regulation
The "Efficacy Gap" Between Animal Models and Human Trials: AOD9604's biggest weakness lies in the uncertainty of its clinical efficacy. Although it demonstrated significant weight loss and lipid-lowering effects in animal models such as obese Zucker rats, subsequent human clinical trials yielded disappointing results. The pivotal Phase IIb clinical trial failed to demonstrate its superiority over placebo in weight loss, with no statistical significance. This revealed potential "species differences" in the translation of its mechanism of action from rodents to humans, preventing the replication of its "miraculous effects" in animals in humans, ultimately leading to the termination of its development as a weight-loss drug.
AOD9604 has never been approved by the FDA or other major regulatory agencies for the treatment of obesity or any other disease. It is currently only defined as an "investigative compound for research use only." This means that AOD9604 products circulating in the market are not subject to drug regulation, and their purity, dosage, and sterility cannot be guaranteed. Users face significant legal and health risks, including product contamination, dosage errors, and unknown long-term side effects.
Due to its potential metabolic modulation capabilities, AOD9604 has been listed as a prohibited substance by the World Anti-Doping Agency (WADA). For professional or competitive athletes, the use of AOD9604 not only poses health risks but could also lead to the end of their careers. This further limits its application in mainstream sports and fitness.
Hot Tags: original manufacturer high purity aod9604, China original manufacturer high purity aod9604 manufacturers, suppliers, factory, Premium Grade Follistatin 344 Laboratory Use Only, High Efficiency HGH 191aa, Potent metabolic regulator Cagrilintide professional version for injection , Wholesale Gonadorelin Peptide Reagent with High Assay, High Efficiency IGF DES, Original Manufacturer High Purity Tesamorelin
